Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy.

Oncoimmunology - 1 Jan 2022

Song Xinxin, Zhou Zhuan, Kang Rui, Tang Daolin

Abstract excerpt

The covalent KRAS-G12C inhibitors (G12Ci) are rapidly changing the treatment landscape for advanced non-small cell lung cancer, but drug resistance remains a clinical challenge. Two recent studies have developed bispecific T cell engagers that form a link between T cells and tumor cells to selectively eliminate G12Ci-resistant cells.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cell Line, Tumor
Share to KRAS gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to T-Lymphocytes

Source

Open in PubMed Open full text

Identifiers

PMID: 36338145
DOI: 10.1080/2162402X.2022.2141978
PMCID: PMC9629117

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy.PMID 36338145Read ↗

Resistance looms for KRAS G12C inhibitors and rational tackling strategies.Semantic proximity Read ↗

With a little help from my T friends: T cells increase efficacy of KRAS (G12D) inhibitors.Semantic proximity Read ↗

Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models.Semantic proximity Read ↗

Targeting Mutant KRAS for Immunogenic Cell Death Induction.Semantic proximity Read ↗

Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade.Semantic proximity Read ↗

Targeting KRAS with reversible inhibitors.Semantic proximity Read ↗

The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

KRAS-mutated Non-Small Cell Lung Cancer: Drugging the Undruggable.Semantic proximity Read ↗

Micellar co-delivery of KRAS-mutant inhibitors and TLR7/8 agonists synergizes targeted therapy and immunotherapy in lung cancer.Semantic proximity Read ↗

EFTX-G12V: a novel KRASG12V-selective RNAi therapeutic.Semantic proximity Read ↗

Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culpritSemantic proximity Read ↗

Combinatorial approaches for mitigating resistance to KRAS-targeted therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.